Clinical Genetic Testing for Hearing Loss: Implications for Genetic Counseling and Gene-Based Therapies.

Genetic factors contribute significantly to congenital hearing loss, with non-syndromic cases being more prevalent and genetically heterogeneous. Currently, 150 genes have been associated with non-syndromic hearing loss, and their identification has improved our understanding of auditory physiology and potential therapeutic targets. Hearing loss gene panels offer comprehensive genetic testing for hereditary hearing loss, and advancements in sequencing technology have made genetic testing more accessible and affordable. Currently, genetic panel tests available at a relatively lower cost are offered to patients who face financial barriers. In this study, clinical and audiometric data were collected from six pediatric patients who underwent genetic panel testing. Known pathogenic variants in MYO15A, GJB2, and USH2A were most likely to be causal of hearing loss. Novel pathogenic variants in the MYO7A and TECTA genes were also identified. Variable hearing phenotypes and inheritance patterns were observed amongst individuals with different pathogenic variants. The identification of these variants contributes to the continually expanding knowledge base on genetic hearing loss and lays the groundwork for personalized treatment options in the future.

The A2ml1-Knockout mouse as an animal model for non-syndromic otitis media.

BACKGROUND: Inflammation and infection of the middle ear, known as otitis media (OM), is a leading cause of hearing loss and the most frequently diagnosed disease in children worldwide. Traditionally, mouse models for OM rely on inducing acute infection through inoculation of the middle ear, e.g. with the human otopathogen non-typeable Haemophilus influenzae (NTHi), and with very few genetic models with spontaneous or chronic OM. A2ML1 variants, including loss-of-function variants, were associated with susceptibility to OM in humans, but no animal model has been reported for A2ml1-related OM. Here, we report our middle ear findings in a mouse line with a CRISPR-induced knockout (KO) of A2ml1. METHODS: Mice were X-rayed prior to harvest to determine if there are craniofacial or skeletal abnormalities. Tissue from mouse middle ears, as well as other upper respiratory mucosal tissues, were harvested. The harvested middle ear bullae were examined under microscope and submitted for histologic preparation to study phenotypic indications of OM. RNA samples isolated from middle ear tissue were assayed for expression of genes correlated with A2ML1 expression in humans. RESULTS: Data from a total of 119 mice (35 wildtype, 40 heterozygous, 44 homozygous) are presented here, with each analyses being performed on subsets of these mice. There were no significant craniofacial differences by genotype (n = 22). Findings in mice with the A2ml1-KO indicated an increased incidence of OM (n=29; odds ratio = 11; CI: 1.1, 573.6; Fisher exact two-sided p = 0.02) with tympanic membrane perforations or thickening, as well as cases of middle ear effusion, inflammatory cells, or fluid from histologic sections. Dsp was upregulated in the middle ear tissues of homozygous mice (Wilcoxon test p = 0.001). CONCLUSION: Thus far, our results in this A2ml1-KO mouse line indicate spontaneous occurrence of OM and dysregulation of Dsp in the middle ear as a potential disease mechanism for A2ml1-related OM.

Cost-analysis of universal newborn hearing screening in the Philippines

OBJECTIVE: The prevalence of congenital bilateral permanent profound hearing loss in the Philippines is 1.3 per 1000 live births. The prevalence increases to 22 per 1000 live births for unilateral mild to moderate hearing loss. This study was conducted to determine the cost of establishing a universal newborn hearing screening (UNHS) program. Local prevalence data and current costs of screening, diagnostics and intervention strategies for bilateral permanent hearing loss were utilized to estimate the costs of implementing the program. METHODS: Both short-term and long-term costs for hearing screening centers and for families caring for hearing-impaired children were determined using a societal perspective. Calculations included cost of hearing loss and the effectiveness of testing strategies. In this study the societal cost was considered although some of the costs pertained to costs borne by individual patients or their families since none of the screening, diagnostic and intervention strategies are paid for by insurance companies. An exception is the partial subsidy for cochlear implantation that is reimbursable with the Philippine Health Insurance Corporation. RESULTS: Using published data on the prevalence of hearing loss and experience from a pilot universal newborn hearing screening project at a national tertiary hospital (Philippine General Hospital), the long-term benefits and savings from UNHS on a national scale greatly outweigh the immediate costs of testing and intervention. CONCLUSION: The cost benefit of UNHS program at a national level outweighs the financial burden of hearing impaired individuals and their families.